JPY1,578.00
0.35% today
Tokyo, Nov 21, 07:15 am CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Stock price

JPY1,572.00
-213.00 11.93% 1M
+70.00 4.66% 6M
-114.00 6.76% YTD
-235.50 13.03% 1Y
-381.50 19.53% 3Y
-246.00 13.53% 5Y
-190.00 10.78% 10Y
Tokyo, Closing price Thu, Nov 21 2024
-0.50 0.03%
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Key metrics

Market capitalization JPY2.81t
Enterprise Value JPY3.56t
P/E (TTM) P/E ratio 51.40
EV/FCF (TTM) EV/FCF 22.03
EV/Sales (TTM) EV/Sales 2.01
P/S ratio (TTM) P/S ratio 1.59
P/B ratio (TTM) P/B ratio 1.84
Dividend yield 4.71%
Last dividend (FY25) JPY74.00
Revenue growth (TTM) Revenue growth 16.32%
Revenue (TTM) Revenue JPY1.77t
EBIT (operating result TTM) EBIT JPY191.26b
Free Cash Flow (TTM) Free Cash Flow JPY161.56b
Cash position JPY292.99b
EPS (TTM) EPS JPY30.60
P/E forward 37.21
P/S forward 1.58
EV/Sales forward 2.00
Show more

Is Astellas Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Astellas Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Astellas Pharma forecast:

8x Buy
53%
6x Hold
40%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Astellas Pharma forecast:

Buy
53%
Hold
40%
Sell
7%

Financial data from Astellas Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,772,155 1,772,155
16% 16%
100%
- Direct Costs 457,269 457,269
38% 38%
26%
1,314,886 1,314,886
10% 10%
74%
- Selling and Administrative Expenses 603,147 603,147
7% 7%
34%
- Research and Development Expense 324,570 324,570
16% 16%
18%
387,169 387,169
10% 10%
22%
- Depreciation and Amortization 195,912 195,912
81% 81%
11%
EBIT (Operating Income) EBIT 191,257 191,257
21% 21%
11%
Net Profit 54,746 54,746
61% 61%
3%

In millions JPY.

Don't miss a Thing! We will send you all news about Astellas Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Naoki Okamura
Employees 14,754
Founded 1923
Website www.astellas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today